Bluebird’s tweaked sickle cell gene therapy clears early test – FierceBiotech
FierceBiotech |
Bluebird’s tweaked sickle cell gene therapy clears early test
FierceBiotech Bluebird bio has posted early clinical data suggesting work to rescue its sickle cell gene therapy may pay off. The tweaked gene therapy triggered a jump in the proportion of vector-positive cells in the two patients treated so far, raising hopes … Bluebird marks progress on Lentiglobin gene therapyBioPharma Dive #ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is workingEndpoints News Gene Therapy in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed …Business Wire (press release) Dispatch Tribunal all 43 news articles » |
Endpoints News |
Juno Therapeutics (JUNO) to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
StreetInsider.com “The presentations at ASH will showcase promising data coming from our pipeline of CD19- and BMCA-directed CAR T cell product candidates,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “Results from the ongoing … #ASH17: The big loser in CAR–T, Juno is making a bid to seize the fast lane to frontrunner statusEndpoints News Head-To-Head Contrast: Juno Therapeutics (NASDAQ:JUNO) versus Its RivalsWeek Herald |
Endpoints News |
Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
Business Wire (press release) “The presentations at ASH will showcase promising data coming from our pipeline of CD19- and BMCA-directed CAR T cell product candidates,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “Results from the ongoing … Head-To-Head Contrast: Juno Therapeutics (NASDAQ:JUNO) versus Its RivalsWeek Herald |
Thorold News |
Bluebird marks progress on Lentiglobin gene therapy
BioPharma Dive New data on Bluebird Bio Inc.’s gene therapy for sickle cell disease suggest manufacturing changes made last fall are boosting the treatment’s potency, although investors looking for more conclusive evidence of improvement will have to wait until later … bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational ProgressBusiness Wire (press release) bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β …Digital Journal bluebird bio (BLUE) Earns Daily Media Sentiment Score of 0.08StockNewsTimes Weekly Register all 31 news articles » |
Endpoints News |
California upstart Xyphos wants to tackle CAR–T’s big problems
Endpoints News If, however, the cancer patient begins experiencing toxicity, the doctor could stop the antibody therapy. The antibody then cycles out of the patient, and the CARs revert to harmless, inactive T cells. Its sort of like switching T cells on and off when … AvidBiotics Splits into Two Biotechnology Companies Each Developing its Distinct Technology PlatformPR Newswire (press release) |